Drug intelligence / Profile preview

butorphanol + dexmedetomidine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination medication consisting of butorphanol, a synthetic opioid agonist-antagonist analgesic, and dexmedetomidine, an α2-adrenoceptor agonist. This combination provides synergistic sedative and analgesic effects, making it useful for procedures requiring moderate to deep sedation and pain control. In human medicine, it's used for procedures like burn dressing changes and microvascular decompression surgeries, while in veterinary medicine it's commonly used for sedation and minor surgical procedures in various species.

Other names: dexmedetomidine and butorphanolDex-But

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)ADRA2A (α2A)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on butorphanol + dexmedetomidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on butorphanol + dexmedetomidine.

Explore the full profile